For NSCLC patients with PD-L1 expression in ≥50% of tumor cells, pembrolizumab confers a superior progression-free survival (PFS) and overall survival (OS) compared with platinum-doublet chemotherapy in the first-line setting (4). Here, CD274 is linked to neoplasm.